~~<i id='CB4F7731C0'><strike id='CB4F7731C0'><tt id='CB4F7731C0'><pre id='CB4F7731C0'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：entertainment 2025-09-28 00:01:16 Page View：9795

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden tests positive for Covid
Next article： What does generative AI mean for health care? We asked experts

focus

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Florida officials tell state schools to teach AP Psychology 'in its entirety'

1:29.STOCKIMAGE/GettyImagesFloridaEducationCommissionerMannyDiaz,Jr.hasinstructedFloridaschooloffici

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

Biotech startup Celsius cuts 75% of staff ahead of first trial start

AdobeLaunchingyourfirstclinicaltrialisthetypeofannouncementmostbiotechexecutiveseagerlyanticipate,ho